Kevin M. Cottrell

697 total citations
21 papers, 413 citations indexed

About

Kevin M. Cottrell is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Kevin M. Cottrell has authored 21 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Organic Chemistry. Recurrent topics in Kevin M. Cottrell's work include Cancer-related gene regulation (13 papers), Peptidase Inhibition and Analysis (4 papers) and Hepatitis C virus research (3 papers). Kevin M. Cottrell is often cited by papers focused on Cancer-related gene regulation (13 papers), Peptidase Inhibition and Analysis (4 papers) and Hepatitis C virus research (3 papers). Kevin M. Cottrell collaborates with scholars based in United States, Germany and France. Kevin M. Cottrell's co-authors include John P. Maxwell, Kai Lin, Chao Lin, Cynthia A. Gates, Yunyi Wei, Robert B. Perni, Yu-Ping Luong, B. Govinda Rao, Debra Brennan and Sue Ma and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kevin M. Cottrell

18 papers receiving 392 citations

Peers

Countries citing papers authored by Kevin M. Cottrell

Since Specialization

Citations

This map shows the geographic impact of Kevin M. Cottrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin M. Cottrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin M. Cottrell more than expected).

Fields of papers citing papers by Kevin M. Cottrell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin M. Cottrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin M. Cottrell. The network helps show where Kevin M. Cottrell may publish in the future.

Co-authorship network of co-authors of Kevin M. Cottrell

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin M. Cottrell. A scholar is included among the top collaborators of Kevin M. Cottrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin M. Cottrell. Kevin M. Cottrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers 2025 ·Translational Oncology ·Kimberly J. Briggs, Kevin M. Cottrell, (unknown), (unknown), Minjie Zhang, Douglas A. Whittington, Wenhai Zhang, (unknown), Satoshi Yoda, (unknown), Samuel R. Meier, Yi Yu, Teng Teng, Alan Huang, John P. Maxwell	6
2	MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models 2025 ·Clinical Cancer Research ·(unknown), Dana C. Borcherding, (unknown), Yang Lyu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anthony P.W. Yuen, (unknown), (unknown), Alan Huang, John P. Maxwell, Kevin M. Cottrell, Kimberly J. Briggs, Angela C. Hirbe	0
3	Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor 2025 ·Organic Process Research & Development ·Jianglin Liang, Hongmin Li, Kevin M. Cottrell, Yong Liu, John P. Maxwell, (unknown), (unknown), Magnus Rönn, Michael Palmieri	0
4	Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion 2025 ·Journal of Medicinal Chemistry ·Kevin M. Cottrell, Kimberly J. Briggs, Alice Tsai, (unknown), Douglas A. Whittington, Shanzhong Gong, (unknown), Patrick McCarren, Minjie Zhang, Wenhai Zhang, Alan Huang, John P. Maxwell	7
5	MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design 2025 ·Journal of Medicinal Chemistry ·Kevin M. Cottrell, Douglas A. Whittington, Kimberly J. Briggs, Haris Jahić, Janid A. Ali, (unknown), Deepali Gotur, (unknown), Wenhai Zhang, Alan Huang, John P. Maxwell	3
6	Abstract 2996: TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrates strong efficacy in combination with clinically relevant targeted therapies in MTAP-null preclinical models 2025 ·Cancer Research ·Minjie Zhang, Alice Tsai, Kevin M. Cottrell, Brian B. Haines, Alan Huang, Jannik N. Andersen, Adam Crystal, Kimberly J. Briggs	1
7	Abstract 4631: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitors 2024 ·Cancer Research ·(unknown), André A. Mignault, Douglas A. Whittington, (unknown), (unknown), (unknown), Satoshi Yoda, Shangtao Liu, Minjie Zhang, Kevin M. Cottrell, Samuel R. Meier, (unknown), (unknown), (unknown), Yi Yu, (unknown), Adam Crystal, Teng Teng, Kimberly J. Briggs	0
8	Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers 2024 ·Journal of Medicinal Chemistry ·Kevin M. Cottrell, Kimberly J. Briggs, Douglas A. Whittington, Haris Jahić, Janid A. Ali, Charles B. Davis, Shanzhong Gong, Deepali Gotur, (unknown), Patrick McCarren, (unknown), Alice Tsai, Erik Wilker, Hongling Yuan, Minjie Zhang, Wenhai Zhang, Alan Huang, John P. Maxwell	34
9	EXTH-63. MTA-COOPERATIVE PRMT5 INHIBITORS ARE EFFICACIOUS IN MTAP-DELETED MALIGNANT PERIPHERAL NERVE SHEATH TUMOR MODELS 2023 ·Neuro-Oncology ·Dana C. Borcherding, Xiaochun Zhang, Minjie Zhang, Himanshi Bhatia, Yang Lyu, (unknown), (unknown), (unknown), (unknown), (unknown), Alan Huang, John P. Maxwell, Kevin M. Cottrell, Kimberly J. Briggs, Angela C. Hirbe	3
10	Abstract 3452: TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models 2023 ·Cancer Research ·Minjie Zhang, (unknown), Kevin M. Cottrell, Brian B. Haines, Erik Wilker, (unknown), (unknown), Alan Huang, Charles B. Davis, John P. Maxwell, Kimberly J. Briggs	3
11	Abstract 4970: TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors 2023 ·Cancer Research ·Kimberly J. Briggs, (unknown), Minjie Zhang, (unknown), Brian B. Haines, Alan Huang, Kevin M. Cottrell	4
12	24P Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model 2022 ·Annals of Oncology ·Karen K. Briggs, (unknown), (unknown), (unknown), (unknown), Erik Wilker, Charles B. Davis, Kevin M. Cottrell, John P. Maxwell, Alan Huang	3
13	Abstract 3941: TNG908 is an MTAPnull-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies 2022 ·Cancer Research ·Kimberly J. Briggs, Kevin M. Cottrell, (unknown), Erik Wilker, (unknown), Charles B. Davis, Minjie Zhang, (unknown), Deepali Gotur, Matthew J. Goldstein, (unknown), Marc S. Rudoltz, Alan Huang, John P. Maxwell	5
14	Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors 2020 ·ACS Medicinal Chemistry Letters ·Upul K. Bandarage, Alex M. Aronov, Jingrong Cao, Jon H. Come, Kevin M. Cottrell, Robert J.O. Davies, Simon Giroux, Marc Jacobs, Sudipta Mahajan, (unknown), Cameron Stuver Moody, (unknown), (unknown)	12
15	Abstract 3716: Potent radiation enhancement with VX-984, a selective DNA-PKcs inhibitor for the treatment of NSCLC 2016 ·Cancer Research ·Diane M. Boucher, Russell R. Hoover, Yuxin Wang, Yong Gu, David Newsome, Pamella J. Ford, Cameron Stuver Moody, Véronique Damagnez, (unknown), Shawn Hillier, Mark Wood, William Markland, Brenda K. Eustace, Kevin M. Cottrell, Marina S. Penney, Brinley F. Furey, Kirk Tanner, John P. Maxwell, Paul S. Charifson	5
16	Structural Basis for Isoform Selectivity in a Class of Benzothiazole Inhibitors of Phosphoinositide 3-Kinase γ 2014 ·Journal of Medicinal Chemistry ·Philip N. Collier, Gabriel Martínez-Botella, Mark Cornebise, Kevin M. Cottrell, John Doran, James P. Griffith, Sudipta Mahajan, François Maltais, Cameron Stuver Moody, (unknown), Tiansheng Wang, Alex M. Aronov	39
17	Inhibitors of hepatitis C virus NS3·4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics 2007 ·Bioorganic & Medicinal Chemistry Letters ·Robert B. Perni, Gurudatt Chandorkar, Kevin M. Cottrell, Cynthia A. Gates, Chao Lin, Kai Lin, Yu-Ping Luong, John P. Maxwell, Mark A. Murcko, J. PITLIK, (unknown), (unknown), (unknown), Yunyi Wei	16
18	Parallel, Solution Phase Synthesis of Dihydropyridine Miticides Via a Versatile Multicomponent Reaction 2005 ·Combinatorial Chemistry & High Throughput Screening ·Kevin M. Cottrell, C. W. Holyoke, (unknown), (unknown), (unknown), (unknown), Syed Shaheen Shah	4
19	In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061 2004 ·Journal of Biological Chemistry ·Chao Lin, Kai Lin, Yu-Ping Luong, B. Govinda Rao, Yunyi Wei, Debra Brennan, John R. Fulghum, (unknown), Sue Ma, John P. Maxwell, Kevin M. Cottrell, Robert B. Perni, Cynthia A. Gates, Ann D. Kwong	228
20	Synthesis and enzymatic evaluation of a P1 arginine aminocoumarin substrate library for trypsin-like serine proteases 2000 ·Bioorganic & Medicinal Chemistry Letters ·Philip D. Edwards, Russell C. Mauger, Kevin M. Cottrell, (unknown), (unknown), Mark Sylvester, Clay W. Scott, Stephen T. Furlong	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact